^
    Back
    Association details:
    Biomarker:MET overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Front Immunol
    Title:

    Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer

    Published date:
    10/05/2023
    Excerpt:
    According to the receiver operating characteristics and Kaplan-Meier curve analyses, patients with high c-MET, EGFR, and VEGFR2 expression at baseline had significantly shorter PFS than those with low expression.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.3389/fimmu.2023.1086479